Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature
ConclusionA very difficult case of grade V immune-related thrombocytopenia after the administration of nivolumab as second-line therapy for relapsed lung adenocarcinoma was described. Immune-related thrombocytopenia is a rare adverse event, but it must be considered a possible complication because it may become critical once it has occurred.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | Chemotherapy | Diabetes | Diabetes Mellitus | Endocrinology | General Medicine | Japan Health | Laboratory Medicine | Lung Cancer | Myasthenia Gravis | Non-Small Cell Lung Cancer | Steroid Therapy | Thrombocytopenia | Toxicology